Karyopharm Therapeutics Inc (NASDAQ:KPTI) insider Sharon Shacham sold 10,000 shares of the stock in a transaction on Monday, January 8th. The shares were sold at an average price of $10.08, for a total transaction of $100,800.00. Following the completion of the sale, the insider now owns 723,510 shares of the company’s stock, valued at approximately $7,292,980.80. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available through this hyperlink.

Sharon Shacham also recently made the following trade(s):

  • On Thursday, December 7th, Sharon Shacham sold 10,000 shares of Karyopharm Therapeutics stock. The shares were sold at an average price of $10.39, for a total transaction of $103,900.00.

Karyopharm Therapeutics Inc (KPTI) opened at $10.01 on Thursday. The firm has a market cap of $472.28, a PE ratio of -3.76 and a beta of 4.08. Karyopharm Therapeutics Inc has a 1 year low of $7.48 and a 1 year high of $14.63.

Karyopharm Therapeutics (NASDAQ:KPTI) last issued its quarterly earnings data on Thursday, November 2nd. The company reported ($0.65) earnings per share for the quarter, missing the Thomson Reuters’ consensus estimate of ($0.64) by ($0.01). Karyopharm Therapeutics had a negative net margin of 67,267.47% and a negative return on equity of 76.83%. equities analysts anticipate that Karyopharm Therapeutics Inc will post -2.58 EPS for the current fiscal year.

KPTI has been the subject of a number of recent analyst reports. HC Wainwright reiterated a “buy” rating and issued a $23.00 price target on shares of Karyopharm Therapeutics in a research note on Tuesday, December 12th. BidaskClub cut shares of Karyopharm Therapeutics from a “hold” rating to a “sell” rating in a research note on Thursday, December 7th. initiated coverage on shares of Karyopharm Therapeutics in a research note on Wednesday, November 15th. They issued a “buy” rating and a $23.00 price target for the company. Royal Bank of Canada reiterated a “buy” rating and issued a $15.00 price target on shares of Karyopharm Therapeutics in a research note on Friday, November 3rd. Finally, Cantor Fitzgerald set a $18.00 price target on shares of Karyopharm Therapeutics and gave the company a “buy” rating in a research note on Thursday, October 12th. One analyst has rated the stock with a sell rating, two have given a hold rating and eight have assigned a buy rating to the company’s stock. Karyopharm Therapeutics currently has a consensus rating of “Buy” and an average price target of $17.33.

Institutional investors and hedge funds have recently modified their holdings of the company. Voya Investment Management LLC raised its position in shares of Karyopharm Therapeutics by 42.1% in the second quarter. Voya Investment Management LLC now owns 15,008 shares of the company’s stock valued at $136,000 after purchasing an additional 4,444 shares during the period. Tudor Investment Corp ET AL bought a new position in shares of Karyopharm Therapeutics in the second quarter valued at about $136,000. State of Wisconsin Investment Board bought a new position in shares of Karyopharm Therapeutics in the second quarter valued at about $235,000. The Manufacturers Life Insurance Company raised its position in shares of Karyopharm Therapeutics by 26.2% in the second quarter. The Manufacturers Life Insurance Company now owns 26,907 shares of the company’s stock valued at $243,000 after purchasing an additional 5,586 shares during the period. Finally, ProShare Advisors LLC raised its position in shares of Karyopharm Therapeutics by 8.0% in the second quarter. ProShare Advisors LLC now owns 27,154 shares of the company’s stock valued at $246,000 after purchasing an additional 2,021 shares during the period. 60.92% of the stock is currently owned by institutional investors.

WARNING: “Sharon Shacham Sells 10,000 Shares of Karyopharm Therapeutics Inc (KPTI) Stock” was originally published by The Cerbat Gem and is the sole property of of The Cerbat Gem. If you are reading this report on another publication, it was copied illegally and republished in violation of United States and international trademark and copyright laws. The legal version of this report can be viewed at https://www.thecerbatgem.com/2018/01/11/sharon-shacham-sells-10000-shares-of-karyopharm-therapeutics-inc-kpti-stock.html.

About Karyopharm Therapeutics

Karyopharm Therapeutics Inc is a clinical-stage pharmaceutical company. The Company is focused on the discovery, development and commercialization of drugs directed against nuclear transport and related targets for the treatment of cancer and other diseases. It has discovered and is developing small molecule Selective Inhibitor of Nuclear Export (SINE) compounds that inhibit the nuclear export protein, XPO1.

Insider Buying and Selling by Quarter for Karyopharm Therapeutics (NASDAQ:KPTI)

Receive News & Ratings for Karyopharm Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Karyopharm Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.